The Rapid Case Ascertainment program (RCA) was developed in 1986-1987 to facilitate population-based studies of cancer that propose to use the state of Connecticut as a population laboratory. It was incorporated as a YCC shared resourced on 1/1/95. RCA functions as a field arm of the Connecticut Tumor Registry, the oldest population-based cancer registry in the country, and since 1973 an NCI SEER site. RCA takes care of the many requirements and administrative tasks common to all proposed hospital- based research in the state, and provides uniformly high-quality interface with those individuals, institutions and agencies who are crucial to the success of population-based cancer prevention and control research. Initiation of hospital-based research in Connecticut is complicated. Individual hospital requirements and personnel are always changing. Prior to RCA, an investigator who had a single study a definitive funding period and perhaps limited knowledge of institutional policies, personalities and politics had to spend an inordinate amount of time on non-scientific related effort to obtain and maintain the necessary approvals to conduct the research. Major services provided to investigators are: consulting and assisting in protocol writing in appropriate areas (protection of human subjects, confidentiality, design of required institution-specific consent documents, etc.); obtaining all non-Yale approvals to conduct the research (State of CT, CT Hospital Association., all community hospital IRBs, hospital administrative and departmental approvals, where necessary); providing names of patients with incident cancers by surveying all hospitals, and when appropriate specific private laboratories, on a regular basis; providing timely status reports and requests for reapprovals to all non-Yale IRBs. RCA services geared to enhance and strengthen the partnership of investigators and data sources are: providing feed-back of all published results of research to involved personnel in participating institutions to counter a past compliant that they never saw the results of research conducted with data they provided; recognizing and acknowledging in print those institutions which participate in the research; and acting as a resource to the health care community in those areas relating to cancer prevention and control, including facilitating interaction between investigators with common interests and goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-25
Application #
6203025
Study Section
Project Start
1999-08-12
Project End
2000-06-30
Budget Start
Budget End
Support Year
25
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications